Orgenesis (ORGS) Competitors $1.00 +0.98 (+4,445.45%) As of 08/27/2025 12:04 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORGS vs. SYBX, LSB, HOTH, LPCN, LEXX, EDSA, COCP, BLRX, MTEX, and NRSNShould you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Synlogic (SYBX), LakeShore Biopharma (LSB), Hoth Therapeutics (HOTH), Lipocine (LPCN), Lexaria Bioscience (LEXX), Edesa Biotech (EDSA), Cocrystal Pharma (COCP), BioLineRx (BLRX), Mannatech (MTEX), and NeuroSense Therapeutics (NRSN). These companies are all part of the "pharmaceutical products" industry. Orgenesis vs. Its Competitors Synlogic LakeShore Biopharma Hoth Therapeutics Lipocine Lexaria Bioscience Edesa Biotech Cocrystal Pharma BioLineRx Mannatech NeuroSense Therapeutics Orgenesis (NASDAQ:ORGS) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation. Which has better valuation & earnings, ORGS or SYBX? Synlogic has lower revenue, but higher earnings than Orgenesis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrgenesis$662K7.25-$55.36MN/AN/ASynlogic$10K1,731.60-$23.36M-$0.08-18.50 Does the media prefer ORGS or SYBX? In the previous week, Orgenesis and Orgenesis both had 1 articles in the media. Synlogic's average media sentiment score of 1.87 beat Orgenesis' score of 0.63 indicating that Synlogic is being referred to more favorably in the news media. Company Overall Sentiment Orgenesis Positive Synlogic Very Positive Which has more volatility & risk, ORGS or SYBX? Orgenesis has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Is ORGS or SYBX more profitable? Synlogic has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Synlogic's return on equity.Company Net Margins Return on Equity Return on Assets Orgenesis-3,827.81% N/A -130.18% Synlogic N/A -8.09%-5.50% Do insiders and institutionals hold more shares of ORGS or SYBX? 22.6% of Orgenesis shares are held by institutional investors. Comparatively, 63.4% of Synlogic shares are held by institutional investors. 5.7% of Orgenesis shares are held by insiders. Comparatively, 3.0% of Synlogic shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummarySynlogic beats Orgenesis on 7 of the 10 factors compared between the two stocks. Get Orgenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGS vs. The Competition Export to ExcelMetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.80M$848.51M$5.78B$9.80BDividend YieldN/A4.84%3.95%4.02%P/E RatioN/A1.1331.2626.59Price / Sales7.2526.55454.13168.41Price / CashN/A19.5637.7359.36Price / Book-0.156.7310.046.68Net Income-$55.36M-$4.20M$3.27B$265.59M7 Day PerformanceN/A15.34%3.17%3.42%1 Month PerformanceN/A16.63%4.34%1.09%1 Year PerformanceN/A33.32%44.12%23.84% Orgenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGSOrgenesis1.616 of 5 stars$1.00+4,445.5%N/AN/A$4.80M$662K0.00150Negative NewsGap UpSYBXSynlogic1.1493 of 5 stars$1.46+1.7%N/A-2.0%$17.02MN/A-0.5880Positive NewsLSBLakeShore Biopharma1.5356 of 5 stars$0.81-1.0%N/A-82.7%$16.87M$85.67M0.00773News CoverageHOTHHoth Therapeutics2.8213 of 5 stars$1.27-1.6%$4.00+215.0%+65.8%$16.84MN/A-1.194Positive NewsLPCNLipocine2.4047 of 5 stars$3.06+1.5%$9.00+194.6%-14.5%$16.56M$11.20M-3.5110Positive NewsLEXXLexaria Bioscience3.7847 of 5 stars$0.84+0.4%$4.00+376.2%-69.1%$16.43M$460K-1.257News CoverageEDSAEdesa Biotech2.2169 of 5 stars$2.33+2.6%$5.00+114.7%-49.0%$16.40MN/A-1.7620Positive NewsGap DownCOCPCocrystal Pharma2.8597 of 5 stars$1.59+1.6%$6.00+278.5%-18.0%$16.37MN/A-1.2910Positive NewsBLRXBioLineRx3.4161 of 5 stars$3.82-0.2%$26.00+579.9%-86.8%$16.17M$28.94M-0.4340MTEXMannatech0.938 of 5 stars$8.43-1.4%N/A+17.2%$16.03M$112.98M-4.13250Gap DownNRSNNeuroSense Therapeutics2.3531 of 5 stars$1.16-7.2%$14.00+1,106.9%+51.1%$15.93MN/A-2.1610 Related Companies and Tools Related Companies Synlogic Alternatives LakeShore Biopharma Alternatives Hoth Therapeutics Alternatives Lipocine Alternatives Lexaria Bioscience Alternatives Edesa Biotech Alternatives Cocrystal Pharma Alternatives BioLineRx Alternatives Mannatech Alternatives NeuroSense Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGS) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access